Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17329152 | 0.92 | BRD4 (0.32) | BRD4CREBBP | |
| SCHEMBL15944797 | 0.86 | BRD4 (0.32) | BRD4CREBBP | |
| SCHEMBL14697153 | 0.86 | KDM4E (0.35) | BRD4CREBBP | |
| SCHEMBL15944686 | 0.85 | BRD4 (0.32) | BRD4CREBBP | |
| SCHEMBL15944917 | 0.85 | BRD4 (0.32) | BRD4CREBBP | |
| SCHEMBL15944658 | 0.81 | DUT (0.36) | BRD4CREBBP | |
| SCHEMBL17350116 | 0.76 | JAK2 (0.33) | BRD4CREBBP | |
| SCHEMBL14708586 | 0.76 | JAK2 (0.33) | BRD4CREBBP | |
| SCHEMBL17272990 | 0.75 | DGAT1 (0.33) | BRD4CREBBP | |
| SCHEMBL16477567 | 0.75 | DGAT1 (0.33) | BRD4CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2955181-B1 | TRICYCLIC PYRROLOPYRIDINE COMPOUND, AND JAK INHIBITOR | NISSAN CHEMICAL CORP (JP) | 2019-10-30 | — | — | EP | disclosed |
| EP-2955181-B1 | TRICYCLIC PYRROLOPYRIDINE COMPOUND, AND JAK INHIBITOR | NISSAN CHEMICAL CORP (JP) | 2019-10-30 | — | — | EP | disclosed |
| US-9475813-B2 | Tricyclic pyrrolopyridine compound, and JAK inhibitor | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-10-25 | — | — | US | disclosed |
| US-9475813-B2 | Tricyclic pyrrolopyridine compound, and JAK inhibitor | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-10-25 | — | — | US | disclosed |
| US-9475813-B2 | Tricyclic pyrrolopyridine compound, and JAK inhibitor | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-10-25 | — | — | US | disclosed |
| US-20150368245-A1 | TRICYCLIC PYRROLOPYRIDINE COMPOUND, AND JAK INHIBITOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-12-24 | — | — | US | disclosed |
| EP-2955181-A1 | TRICYCLIC PYRROLOPYRIDINE COMPOUND, AND JAK INHIBITOR | Nissan Chemical Industries, Ltd. (JP) | 2015-12-16 | — | — | EP | disclosed |
| EP-2955181-A1 | TRICYCLIC PYRROLOPYRIDINE COMPOUND, AND JAK INHIBITOR | Nissan Chemical Industries, Ltd. (JP) | 2015-12-16 | — | — | EP | disclosed |
| WO-2014123167-A1 | TRICYCLIC PYRROLOPYRIDINE COMPOUND, AND JAK INHIBITOR | 日産化学工業株式会社 (JP) | 2014-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368245-A1 | TRICYCLIC PYRROLOPYRIDINE COMPOUND, AND JAK INHIBITOR | JAK1, JAK2, JAK3 | BRD4 429/4885CREBBP 2257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.